Updates are available Correction dated 2021-09-25
Click to view Correction: https://doi.org/10.1007/s12282-021-01296-z
-
Authors
Taira, Naruto http://orcid.org/0000-0003-4266-1117
Kashiwabara, Kosuke
Tsurutani, Junji
Kitada, Masahiro
Takahashi, Masato
Kato, Hiroaki
Kikawa, Yuichiro
Sakata, Eiko
Naito, Yoichi
Hasegawa, Yoshie
Saito, Tsuyoshi
Iwasa, Tsutomu
Takashima, Tsutomu
Aihara, Tomohiko
Mukai, Hirofumi
Hara, Fumikata
-
Funding
Funding for this research was provided by:
Taiho Pharmaceutical
- License Information
-
More Information
Article History
Received: 5 June 2021
Accepted: 25 August 2021
First Online: 7 September 2021
Change Date: 25 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12282-021-01296-z
Declarations
:
: Junji Tsurutani has received research funds from Daiichi Sankyo; honoraria from Novartis, Taiho, Eisai, Chugai, and Kyowa Kirin; personal fees for participating in advisory boards for Eisai and Asahi Kasei; and support for travel expenses from Daiichi Sankyo. Masato Takahashi has received an honorarium for a lecture from Taiho. Yoichi Naito has received research funds from Roche Diagnostics; and honoraria for lectures from Roche Diagnostics, Novartis, Eisai, Chugai Pharmaceutical, Fuji Film Toyama Chemistry, and Taiho. Hirofumi Mukai has received honoraria from Pfizer, Takeda, Daiichi Sankyo and Taiho; and research grants from the Japanese government, Daiichi Sankyo, and Pfizer. Hirofumi Mukai is a member of the Board of Directors of the Japan Breast Cancer Society.
: This study was reviewed and approved by independent ethics committees and institutional review boards. Written informed consent was obtained from all patients.
: Due to the nature of this research, participants in the study did not agree for their data to be shared publicly, so supporting data are not available.
Free to read: This content has been made available to all.
